Stock Price Analysis of Vertex Pharmaceuticals Incorporated (VRTX)

Cornelia Mascio
Settembre 13, 2017

The original version of this article can be accessed at The company now has an average rating of "Hold" and a consensus target price of $102.80. The price/earnings to growth ratio (PEG ratio) is a stock's price-to-earnings (P/E) ratio divided by the growth rate of its earnings for a specified time period.

A number of other research analysts also recently issued reports on VRTX. It is positive, as 48 investors sold Vertex Pharmaceuticals Incorporated shares while 165 reduced holdings. UBS AG reaffirmed a "buy" rating and set a $135.00 target price (up previously from $132.00) on shares of Vertex Pharmaceuticals in a report on Friday, May 19th. Zacks Investment Research downgraded shares of Vertex Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, August 4th. Finally, Vetr cut shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "buy" rating and set a $85.33 price target for the a research report on Tuesday, December 6th. Finally, Argus boosted their price target on shares of Vertex Pharmaceuticals from $71.46 to $175.00 and gave the stock a "buy" rating in a research report on Tuesday, August 1st. J.P. Morgan maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Wednesday, July 19.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), maintained return on investment for the last twelve months at -, higher than what Reuters data shows regarding industry's average. Its traded volume of 1.06 Million shares made it active as comparison to average volume of 1896.44. The stock's 50 day moving average is $155.29 and its 200 day moving average is $125.51.

Vertex Pharmaceuticals has a 52 week low of $71.46 and a 52 week high of $167.85 with a P/E ratio of 152.57 The company's market cap is now $0. ALTSHULER DAVID sold $20,701 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday, May 15. The pharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.33. The Return on Investment (ROI) ratio of Vertex Pharmaceuticals Incorporated (VRTX) is -0.3 percent. The company earned $458.71 million during the quarter, compared to analysts' expectations of $453.40 million. During the same period in the previous year, the firm posted $0.24 EPS. Equities analysts forecast that Vertex Pharmaceuticals Incorporated will post $1.60 earnings per share for the current year.

BioMarin Pharmaceutical Inc. most recently reported earnings per share (EPS) of -$0.21 for the June 2017 versus $1.08 in the same quarter previous year, representing -119% growth. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and worldwide copyright legislation. A lower P/B ratio could mean that the stock is undervalued.

In other Vertex Pharmaceuticals news, CMO Jeffrey Chodakewitz sold 5,157 shares of the stock in a transaction that occurred on Wednesday, June 21st. The share price is now up 11.54% for the past three months. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Stuart A. Arbuckle sold 2,125 shares of the company's stock in a transaction on Monday, July 31st. Regal Investment Advisors Llc sold 3,810 shares as Disney Walt Co (DIS)'s stock declined 2.31%. The disclosure for this sale can be found here. Buckingham Asset Management LLC now owns 2,265 shares of the pharmaceutical company's stock worth $292,000 after acquiring an additional 79 shares in the last quarter. Guardian Life Insurance Co. of America lifted its position in shares of Vertex Pharmaceuticals by 0.6% during the first quarter. Achmea Investment Management B.V. boosted its holdings in Vertex Pharmaceuticals by 68.0% in the second quarter.

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded down -0.36% in the last session while performance was up 158.83% in the last five days. Capital World Investors increased its stake in shares of Vertex Pharmaceuticals by 2.8% in the third quarter. Jennison Associates LLC increased its stake in shares of Vertex Pharmaceuticals by 74.2% in the third quarter. Institutional investors and hedge funds own 97.19% of the company's stock.

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE